BeiGene: FDA Defers Action On BLA For Tislelizumab Due To Travel Restrictions

BeiGene (BGNE) announced the FDA has deferred action on the Biologics License Application for tislelizumab as a second-line treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma. The FDA is deferring action on the application as it has been unable to conduct required inspections in China due to COVID-19 related travel restrictions. In September 2021, the FDA accepted the BLA for tislelizumab and provided a PDUFA goal date of July 12, 2022.

BeiGene and Novartis will continue to work with the FDA to support scheduling the required inspections as soon as possible.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
SpaceX, owned by Elon Musk, has launched 40 satellites of British communications network OneWeb into orbit. From NASA's Kennedy Space Center or KSC in Florida, Falcon 9 rocket on Thursday evening carried the satellites. The Falcon 9's first stage separated, and it then returned to Earth to make a landing on a SpaceX pad at the nearby Cape Canaveral Space Force Station. Google, owned by Alphabet Inc., plans to merge its teams working on Maps products and the mapping service Waze with effect from December 9, reports said. The decision to consolidate processes comes as the search giant is facing pressure to streamline operations and cut costs. The restructuring is expected to reduce overlapping work across the Waze and Maps products. The Pentagon announced that up to $9 billion worth of cloud-computing contracts were awarded to Google, Oracle, Amazon, and Microsoft. In a statement, the U.S. Department of Defense said, "The purpose of this contract is to provide the Department of Defense with enterprise-wide, globally available cloud services across all security domains and classification levels..."
Follow RTT